Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage OMS1
- Development stage
- Preclinical
- Lead developer
- Hebrew University of Jerusalem
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
Bacteriophage OMS1 is a lytic bacteriophage targeting *Staphylococcus aureus*, sourced from the Israeli Phage Bank. It is being evaluated for its lytic and anti-biofilm activity against clinical *S. aureus* isolates, including methicillin-resistant *S. aureus* (MRSA) and methicillin-susceptible *S. aureus* (MSSA). Research has focused on its potential application in treating biofilm-mediated left ventricular assist device (LVAD) infections and respiratory tract infections via inhalation.
- Other names
- OMS1 phageOMS-1 phageOMS 1 phageStaphylococcus aureus bacteriophage OMS1Staphylococcus aureus phage OMS1
Beyond the preview
Go deeper on bacteriophage OMS1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage OMS1.